Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review

Sebastian Brandner1,2 | Alexandra McAleenan3 | Hayley E. Jones3 | Ashleigh Kernohan4 | Tomos Robinson4 | Lena Schmidt3 | Sarah Dawson3 | Claire Kelly3 | Emmelyn Spencer Leal5 | Claire L. Faulkner5 | Abigail Palmer5 | Christopher Wragg5 | Sarah Jefferies6 | Luke Vale4 | Julian P. T. Higgins3 | Kathreena M. Kurian3,7

1Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK
2Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK
3Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
4Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
5Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, Bristol, UK
6Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
7Bristol Medical School: Brain Tumour Research Centre, Public Health Sciences, University of Bristol, Bristol, UK

Correspondence
Kathreena M. Kurian, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Email: kathreena.kurian@bristol.ac.uk
Sebastian Brandner, Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.
Email: s.brandner@ucl.ac.uk

Funding information
MRC-NIHR, Grant/Award Number: MR/T044594/1; NIHR Bristol Biomedical Research Centre; Cancer Research UK; Grant/Award Numbers: C18281/A29019, C18281/A19169; National Institute for Health Research

Abstract
Codeletion of chromosomal arms 1p and 19q, in conjunction with a mutation in the isocitrate dehydrogenase 1 or 2 gene, is the molecular diagnostic criterion for oligodendroglioma, IDH mutant and 1p/19q codeleted. 1p/19q codeletion is a diagnostic marker and allows prognostication and prediction of the best drug response within IDH-mutant tumours. We performed a Cochrane review and simple economic analysis to establish the most sensitive, specific and cost-effective techniques for determining 1p/19q codeletion status. Fluorescent in situ hybridisation (FISH) and polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) test methods were considered as reference standard. Most techniques (FISH, chromogenic in situ hybridisation [CISH], PCR, real-time PCR, multiplex ligation-dependent probe amplification [MLPA], single nucleotide polymorphism [SNP] array, comparative genomic hybridisation [CGH], array CGH, next-generation sequencing [NGS], mass spectrometry and NanoString) showed good sensitivity (few false negatives) for detection of 1p/19q codeletions in glioma, irrespective of whether FISH or PCR-based LOH was used as the reference standard. Both NGS and SNP array had a high specificity (fewer false positives) for 1p/19q codeletion when considered against FISH as the reference standard. Our findings suggest that G banding is not a suitable test for 1p/19q analysis. Within these limits, considering cost per diagnosis and using FISH as a reference, MLPA was marginally more cost-effective than other tests, although these economic analyses were limited by the range of available parameters, time horizon and data from multiple healthcare organisations.

KEYWORDS
1p/19q codeletion, false negative, false positive, fluorescent in situ hybridisation, oligodendroglioma, PCR
INTRODUCTION

Complete deletion of both the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) (1p/19q codeletion) is a chromosomal alteration that occurs in oligodendrogliomas, but to date, the best method to detect such deletions is unclear. The codeletion is thought to be an early event in oligodendroglioma tumorigenesis [1] and is thought to be a result of an unbalanced whole-arm translocation between chromosomes 1 and 19 with the loss of the resulting hybrid chromosome [2, 3] (Figure 1). The combined presence of an IDH1 or IDH2 mutation and a 1p/19q codeletion is a diagnostic criterion for oligodendroglioma, IDH mutant and 1p/19q codeleted [8]. The diagnostic test algorithm of IDH-mutant gliomas has been streamlined in a recent consensus publication cIMPACT-NOW update 5 [9], recommending that 1p/19q testing is not required in IDH-mutant astrocytic tumours with loss of nuclear ATRX expression. Although this recommendation reduces the number of 1p/19q tests in IDH-mutant gliomas, the diagnosis of oligodendroglioma, IDH mutant and 1p/19q codeleted, central nervous system (CNS) World Health Organization (WHO) Grade 2 or 3 still requires the detection of an IDH mutation and a 1p/19q codeletion. The European guidelines recommend that 1p/19q status is evaluated to support a diagnosis of oligodendroglioma, IDH mutant and 1p/19q codeleted, and for prognosis, and that treatment decisions are based on the 1p/19q status [10–12]. Current guidance from the National Institute for Health and Care Excellence (NICE) (United Kingdom) recommends and the 2021 CNS WHO classification [13] mandates testing 1p/19q codeletion to identify oligodendrogliomas, and the adjuvant chemo-therapeutic recommended after surgery for people with CNS WHO Grade 3 glioma varies according to 1p/19q status (NICE 2018) [14].

1p/19q status can be determined by several different methods, and there is no consensus regarding the optimal method. The two most common methods for routine diagnostic use are FISH- and polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) assays [15]. In the 2017 UK Cytogenomic External Quality Assessment Service (CEQAS) report, of the 35 enrolled laboratories, 25 laboratories used FISH, 1 laboratory used multiplex ligation-dependent probe amplification (MLPA), 4 laboratories used arrays and 1 laboratory used quantitative PCR.

Implementation and use of these techniques depend on infrastructure and economic circumstances of a country and of individual pathology departments. Therefore, the review considered the costs and the cost-effectiveness of alternative methods assessing 1p/19q status. Each method incurs costs for laboratory, hospital occupancy and subsequent treatment. The benefits of targeted treatment may include greater survival and less exposure to potentially toxic treatments.

A recent systematic review and meta-analysis of the prognostic value of chromosomal 1p/19q codeletion in CNS WHO Grade 2 and 3 oligodendrogliomas found a summary hazard ratio (HR) for mortality of 0.28 (95% confidence interval [CI] 0.13 to 0.62; 9 studies) favouring 1p/19q codeletion after adjusting for age, extent of resection, IDH mutation and type of therapy [16]. Another systematic review and meta-analysis found that 1p/19q codeletion was associated with increased overall survival (HR 0.43; 95% CI 0.35–0.53; 14 studies) [17], both in WHO low-grade (HR 0.45; 95% CI 0.30–0.68; 5 studies) and high-grade oligodendrogliomas (HR 0.41; 95% CI 0.31–0.53; 6 studies), and for astrocytic tumours (HR 0.52; 95% CI 0.36–0.75; 3 studies) and oligodendrogial tumours (HR 0.41; 95% CI 0.30–0.56; 9 studies) [17]. This review also observed no evidence of difference in the HR for overall survival between studies using two different techniques (PCR-based LOH and FISH) to assess the status of chromosomal arms 1p and 19q [17]. It is important to note that these studies were carried out before the current definition of oligodendroglioma, which now mandates the presence of an IDH mutation and a 1p/19q codeletion.

1p/19q codeletion can be absolute, that is, loss in the presence of the normal number of other chromosomes, or relative if it occurs in the presence of polysomy (when cells contain at least one more copy of a chromosome than normal) or polyploidy (when cells contain more than two sets of chromosomes) (Figure 1B–D). Several studies have suggested that people with relative 1p/19q codeletions (deletions in the presence of polysomy or polyploidy) have a worse prognosis (progression free survival or overall survival) than people with absolute 1p/19q codeletions, with some studies suggesting that prognosis in patients with relative codeletions may be similar to that of people with no codeletion at all [4–6, 18]. In all these studies, classification of polysomy occurred when more than 30% of nuclei had more than two 1q and 19p signals, as assessed by FISH (Figure 1E). Although there are limitations to these studies, for example, non-standardised treatment, these findings suggest that diagnosing absolute deletions is more important. The Cochrane review focuses primarily on detection of absolute deletions and in diagnosing situations where one copy of 1p/19q has been lost and the other copy duplicated (also termed copy-neutral LOH). Combinations of chromosomal deletions in oligodendrogliomas and the corresponding signals in FISH are presented in a schematic representation in Figure 1.

In addition to the significant clinical implications associated with the diagnostic accuracy of techniques to diagnose 1p/19q codeletion
status in oligodendroglioma patients, there are also significant potential resource implications regarding the accuracy of the test. The estimated costs associated with clinical care for a patient with glioma ranged between US$ 4755 and US$ 42,907, with reported costs converted into 2013 US $ using an exchange rate based on purchasing power parities [19]. It was also estimated that 55% of these costs were attributable to chemotherapy drugs, chiefly temozolomide. If these therapies can be targeted at those patients who will obtain the greatest benefit, this will make better use of limited healthcare resources.

This review will assess the sensitivity and specificity of any DNA-based techniques that can be used on tumour tissue to evaluate 1p/19q codeletion status directly involved when performing the different test methods. In addition, a cost-effectiveness model was developed to equate costs against the diagnostic performance of each of the diagnostic test methods.

METHODS

The protocol for the review was published in the Cochrane Database of Systematic Reviews [20], and the review was undertaken and reported following Cochrane’s guidance (which is consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA]) [21]. A more detailed account of the methods and results can be found in the full Cochrane publication [20].

Study eligibility

We included cross-sectional studies that use two or more tests to assess 1p/19q status in tumour tissue from the same set of people. Studies needed to present either raw data or classified results for patients for at least two tests. Studies that reported only on concordance of test results were not included. Studies with data for just one person were excluded. For the integrated review of economic evidence, we sought cost and full economic evaluations (cost-effectiveness analyses, cost-utility analyses and cost–benefit analyses) that had been conducted alongside any study designs or as part of a modelling exercise. Participants were adults (≥18 years old) with glioma. Studies in which participants were recruited on the basis of their 1p/19q codeletion status were excluded.

Search methodology

Searches included MEDLINE Ovid (1946–2019), Embase Ovid (1974–2019) and BIOSIS Citation Index (1969–2019). No restriction of language or date of publication was applied. Further searches included OpenGrey (http://www.opengrey.eu/), dissertations and theses (ProQuest Dissertations & Theses Global [https://search.proquest.com/pqdtglobal/dissertations/]) and the Networked Digital Library of Theses and Dissertations (http://search.ndltd.org/index.php). Abstracts from meetings of the Society for Neuro-Oncology (SNO) and its partner associations, the European Association of Neuro-Oncology (EANO) and the Japan Society of Neuro-Oncology, were searched via the Web of Science Conference Proceedings Citation Index (CPCI-S) (1990–2019). We also searched for any ongoing studies via the WHO International Clinical Trials Registry Platform (ICTRP) (all available years to 2019). Further studies were identified from reference lists of included studies. For the integrated review of economic evidence, suitable studies were searched in MEDLINE and Embase, and the National Health Service (NHS) Economic Evaluation Database (EED).

Study selection, data extraction and quality assessment

We used EPPI-Reviewer 4 (https://eppi.ioe.ac.uk) for processes of screening and selection of studies and for part of the data extraction [22]. Data were extracted and further analysed in Microsoft Excel. Two review authors (‘reviewers’) independently screened titles and abstracts of all identified search results and determined whether full texts should be retrieved. Then, two reviewers independently assessed the full-text articles. Disagreements were resolved either by consensus or by consulting a third reviewer. A PRISMA [21] flow diagram was established to describe the flow of information through the different phases of the review (Figure 2).

Studies that met the inclusion criteria for diagnostic test accuracy (DTA) were screened by one reviewer to assess if any could possibly meet the economic inclusion criteria. Had any potentially relevant studies been identified, they would have been screened by two reviewers.

Two reviewers assessed risk of bias and applicability of the DTA studies using the QUADAS-2 tool [23] tailored to our review.
Disagreements were resolved by consensus, with discussion with a third review author if necessary.

**Index tests and target conditions**

Studies using any DNA-based technique to determine 1p/19q status in tumour tissue were included, whereas studies using immunohistochemically detection of 1p/19q status, or studies assessing 1p/19q status from blood samples of imaging, were excluded. The target condition was an absolute 1p/19q codeletion, that is, in the absence of polysomy. As described in Table 1, each of the tests can potentially generate false positive and false negative results. As such, there is no true ‘gold standard’ reference test and all tests are considered to be ‘index tests’. However, in order to estimate the sensitivity and specificity of each test, we considered two alternative reference standards: (i) using FISH as the reference standard, that is, assuming that FISH has 100% sensitivity and specificity, and (ii) using PCR-based LOH assays as the reference standard, that is, assuming that PCR-based LOH assays have 100% sensitivity and specificity. The use of FISH or PCR-based LOH assays was not an inclusion criterion: All studies that used two or more tests to assess 1p/19q status in tumour tissue from the same set of people were included in the review.
| Technique | Acronym | Description of the technique | Quality of the evidence (GRADE) reference standard: FISH | Participants (studies) | Sensitivity [95% CI] | Specificity | Codel FISH detected\(^a\) | Correct positive\(^a\) | False negative\(^a\) | No codel FISH\(^a\) | Correct negative\(^a\) | False positive\(^a\) |
|-----------|---------|-----------------------------|-------------------------------------------------|----------------------|---------------------|------------|--------------------------|------------------|-----------------|---------------------|---------------------|---------------------|
| Fluorescent in situ hybridisation | FISH | Fluorescently labelled probes hybridise to specific chromosomal regions. Can be performed on FFPE, preserves tissue architecture, assessed by fluorescent microscopy | Reference standard | 38 (1) | 1.00 [0.84–1.00] | 0.92 [0.33–1.00] | 31 | 31 | 0 | 69 | 63 | 6 |
| Chromogenic in situ hybridisation | CISH | Chromogenic-labelled probes hybridise to specific chromosomal regions. Can be performed on FFPE, preserves tissue architecture, assessed by bright-field microscopy | Low certainty evidence: rated down due to high imprecision | 915 (15) | 0.94 [0.83–0.98] | 0.94 [0.87–0.98] | 31 | 28 | 3 | 69 | 65 | 3 |
| PCR-based LOH assays (also known as PCR-based short tandem repeat or microsatellite analysis) | PCR-based LOH | Analysis of polymorphic microsatellites dispersed throughout the genome. Different alleles have different numbers of repeats, resulting in different length PCR products. PCR of these regions in individuals with two different alleles (heterozygous) results in two different length products. If heterozygosity is lost, only one length product will be obtained. An individual must be heterozygous for a microsatellite for it to be informative, and DNA from normal tissue is required to determine this. Primers that amplify regions containing microsatellites on 1p and 19q can be used to determine whether 1p and 19q are codeleted. No consensus exists on location or number of microsatellites analysed | Low certainty evidence: rated down due to risk of bias and indirectness | 915 (15) | 0.94 [0.83–0.98] | 0.94 [0.87–0.98] | 31 | 28 | 3 | 69 | 65 | 3 |
| Technique | Acronym | Description of the technique | Quality of the evidence (GRADE) reference standard: FISH | Participants (studies) | Sensitivity [95% CI] | Specificity | Codetd FISH detecteda | Correct positivea | False negativea | No codel FISHa | Correct negativea | False positivea |
|-----------|---------|------------------------------|--------------------------------------------------|------------------------|----------------------|------------|----------------------|----------------|----------------|----------------|----------------|---------------|
| Restriction fragment length polymorphism analysis | RFLP | Restriction enzymes recognising specific sequences cut genomic DNA into fragments of specific sizes. Different alleles may contain cut sites, or the DNA fragment that the restriction enzyme produces after digestion may be expected to differ due to different numbers of repeats in different alleles. Therefore, in a similar manner to PCR, LOH can be detected through loss of fragments of a specific size from informative loci (where an individual is heterozygous in normal tissue) | No results | | | | | | | | | |
| Comparative quantitative PCR, real-time PCR | qPCR | Comparison of PCR product (amplicon) from 1p/19q with amplicon obtained from other chromosomal regions. A deletion results in reduced amplicon, which can be quantified by comparison with the reference amplicon | Very low certainty evidence: rated down due to high risk of bias, high imprecision and indirectness | 40 (2) | 0.81 [0.20–0.99] | 1.00 [0.95–1.00] | 31 | 25 | 6 | 69 | 69 | 0 |
| Multiplex ligation-dependent probe amplification | MLPA | Use of 'split' probes containing that hybridise to specific genomic regions and also contain primer binding sites. Following hybridisation, a ligation step joins adjacent probes, which are subsequently amplified at the primer binding sites by PCR. Only ligated pairs will be amplified. PCR products are separated by length, quantified, normalised internally and compared with reference samples | Very low certainty evidence: rated down due to risk of bias, high imprecision and indirectness | 33 (2) | 0.96 [0.44–1.00] | 0.68 [0.20–0.95] | 31 | 30 | 1 | 69 | 47 | 22 |
| Comparative genomic hybridisation | CGH | Tumour and normal tissue genome (can be from different people) are differentially labelled with two different fluorochromes and then simultaneously hybridised | Low certainty evidence: rated down due to risk of bias and imprecision | 75 (4) | 0.95 [0.59–1.00] | 0.99 [0.90–1.00] | 31 | 31 | 0 | 69 | 63 | 6 |

(Continues)
| Technique                  | Acronym | Description of the technique                                                                 | Quality of the evidence (GRADE) reference standard: FISH | Participants (studies) | Sensitivity [95% CI] | Specificity | Codel FISH detected | Correct positive | False negative | No codel FISH | Correct negative | False positive |
|----------------------------|---------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------|------------------------|----------------------|-------------|--------------------|-----------------|----------------|----------------|-----------------|-----------------|
| Array CGH                  | aCGH    | Same principles as CGH, but instead of the two genomes being competitively hybridised to metaphase chromosomes, they are hybridised to a microarray. The theoretical resolution of aCGH is greater than that of traditional CGH | Very low certainty evidence: rated down due to risk of bias, imprecision and indirectness | 39 (3)                 | 1.00 [0.89–1.00]     | 0.91 [0.55–0.99] | 31                 | 31              | 0               | 69             | 63              | 6               |
| Single nucleotide polymorphism arrays | SNP array | DNA microarray to determine copy number and genotype, can detect gains, losses and copy-neutral LOH. SNPs are variations at a single position in a DNA sequence, one copy of each SNP position inherited from each parent resulting in genotypes AA, AB or BB. To detect abnormalities using SNP arrays, sample DNA is fragmented, labelled and hybridised to an array containing immobilised allele-specific oligonucleotide probes and signal intensity of individual probes measured and copy numbers are calculated | Very low certainty evidence: rated down due to risk of bias, imprecision and indirectness | 111 (6)                | 0.90 [0.57–0.99]     | 0.97 [0.84–1.00] | 31                 | 28              | 3               | 69             | 67              | 2               |
| Methylation arrays         |         | The main purpose of methylation arrays is the measurement of specific regions of the genome that may be modified by methylation and the methylation profile is compared with a reference set of tumours. The array has two probes for each region, one for the methylated and one for unmethylated. To | No results |                        |                      |                        |                        |                    |                  |                |                 |                 |                 |

(Continues)
| Technique            | Acronym | Description of the technique                                                                 | Participants (studies) | Sensitivity [95% CI] | Specificity | Codel FISH detected\(^a\) | Correct positive\(^a\) | False negative\(^a\) | No codel FISH\(^b\) | Correct negative\(^a\) | False positive\(^a\) |
|----------------------|---------|-----------------------------------------------------------------------------------------------|------------------------|----------------------|-------------|--------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Next-generation sequencing | NGS     | NGS refers to post-Sanger sequencing technologies including sequencing by synthesis, sequencing by ligation and ion semiconductor sequencing. Although traditional Sanger sequencing sequences a single-DNA sequence, NGS is capable of sequencing multiple sequences simultaneously. Techniques have been developed to detect LOH and copy number variations using NGS. Deletions can be detected by relative perturbations in the read depth. LOH can be detected when the ratio of alleles at a heterozygous SNP site is perturbed. Low certainty evidence: rated down due to risk of bias and indirectness. | 243 (6)               | 0.94 [0.75–0.99] | 1.00 [0.99–1.00] | 31           | 29                    | 2                    | 69                   | 69                   | 0                    |

Note: Orange fields indicate reference standard. Blue fields indicate techniques used in studies and were compared to a reference standard. Grey fields indicate studies for which no reference standard was available.

\(^a\)Narrative for these fields: All hypothetical scenarios assume that 31 people out of 100 with glioma will have a FISH-detected 1p/19q codeletion. Taking the example of CISH: Of these, 31 people will be given the correct positive result and 0 people will be given a false negative result; of the 69 people without the codeletion, 68 people will be given a correct negative result and 1 people will be given a false positive result.

\(^b\)Narrative for these fields: All hypothetical scenarios assume that 31 people out of 100 with glioma will have a PCR-based LOH-detected 1p/19q codeletion. Taking the example of NGS: Of these, 31 people will be given the correct positive result and 0 people will be given a false negative result. Of the 69 people without the codeletion, 68 people will be given a correct negative result and 1 people will be given a false positive result.
| Technique | Quality of the evidence (GRADE) reference standard: PCR-based LOH | Participants (studies) | Sensitivity [95% CI] | Specificity | Codel PCR detected | Corr positive | False negative | No codel PCR | Correct negative | False positive |
|-----------|--------------------------------------------------------------|------------------------|---------------------|-------------|-------------------|--------------|----------------|--------------|----------------|---------------|
| Fluorescent in situ hybridisation | Low certainty evidence: rated down due to risk of bias and indirectness | 915 (15) | 0.91 [0.78-0.97] | 0.96 [0.90-0.99] | 31 | 28 | 3 | 69 | 66 | 3 |
| Chromogenic in situ hybridisation | No results | | | | | | | | | |
| PCR-based LOH assays (also known as PCR-based short tandem repeat or microsatellite analysis) | Reference standard | | | | | | | | | |
| Restriction fragment length polymorphism analysis | No results | | | | | | | | | |
| Comparative quantitative PCR, real-time PCR | Very low certainty evidence: rated down due to risk of bias, imprecision and indirectness | 10 (1) | 1.00 [0.77–1.00] | NA | 31 | 31 | 0 | _ | _ | _ |
| Multiplex ligation-dependent probe amplification | Very low certainty evidence: rated down due to high risk of bias and indirectness | 18 (1) | 1.00 [0.74–1.00] | 1.00 [0.83–1.00] | 31 | 31 | 0 | 69 | 69 | 0 |
| Comparative genomic hybridisation | Low certainty evidence: rated down due to risk of bias and indirectness | 151 (6) | 0.94 [0.74–0.99] | 0.98 [0.91–1.00] | 31 | 29 | 2 | 69 | 68 | 1 |
| Array CGH | Low certainty evidence: rated down due to high risk of bias | 57 (4) | 1.00 [0.97–1.00] | 0.96 [0.75–1.00] | 31 | 31 | 0 | 69 | 69 | 0 |
| Single nucleotide polymorphism arrays | Very low certainty evidence: rated down due to risk of bias and high imprecision | 33 (2) | 0.97 [0.50–1.00] | 1.00 [0.92–1.00] | 31 | 30 | 1 | 69 | 69 | 0 |
| Methylation arrays | No results | | | | | | | | | |
| Next-generation sequencing | Very low certainty evidence: rated down due to risk of bias, imprecision and indirectness | 49 (1) | 1.00 [0.86–1.00] | 0.98 [0.64–1.00] | 31 | 31 | 0 | 69 | 68 | 1 |

Note: Orange fields indicate reference standard. Blue fields indicate techniques used in studies and were compared to a reference standard. Grey fields indicate studies for which no reference standard was available.

**Narrative for these fields:** All hypothetical scenarios assume that 31 people out of 100 with glioma will have a FISH-detected 1p/19q codeletion. Taking the example of CISH: Of these, 31 people will be given the correct positive result and 0 people will be given a false negative result; of the 69 people without the codeletion, 68 people will be given a correct negative result and 1 person will be given a false positive result.

**Narrative for these fields:** All hypothetical scenarios assume that 31 people out of 100 with glioma will have a PCR-based LOH-detected 1p/19q codeletion. Taking the example of NGS: Of these, 31 people will be given the correct positive result and 0 people will be given a false negative result. Of the 69 people without the codeletion, 68 people will be given a correct negative result and 1 person will be given a false positive result.
**Statistical analysis and data synthesis**

For analysis with each of the respective reference standards (FISH or PCR-based LOH tests), we performed bivariate meta-analyses of the sensitivity and false positive rate (1-specificity) of each index test, assuming binomial likelihoods for the number of ‘true positive’ and ‘true negative’ test results ($2 \times 2$ table) [24, 25]. This approach allows for heterogeneity in sensitivity and specificity across studies and for between-study correlation in these measures. In our main analyses, we assumed that this between-study correlation and the standard deviation (heterogeneity) parameters were shared (i.e., identical) across tests. For studies comparing more than one test with the reference standard, multiple $2 \times 2$ tables were derived.

**Economic model: Base-case analysis**

In addition to the clinical analysis of the results, this study includes a model-based cost-effectiveness analysis to compare the costs and diagnostic performance of the different tests. The model is a mathematical framework that can be used to estimate the consequences of healthcare decisions [26]. This model took the form of a decision tree, and the time horizon for this model was until diagnosis. As such, this model does not include costs and health outcomes beyond diagnosis.

The data required for the model included the prevalence of glioma, the sensitivity and specificity of the tests, and the cost of providing the tests. Prevalence of glioma was derived from the results of the meta-analysis. The sensitivity and specificity values that were calculated in the meta-analysis were utilised in the decision model. For the cost values, intervention costs were derived from both expert opinions from within the Newcastle upon Tyne Hospitals NHS Foundation Trust based on internal costings (costs for FISH and chromogenic in situ hybridisation [CISH], real-time PCR and PCR-based LOH, MLPA and single nucleotide polymorphism [SNP] array), whereas cost for next-generation sequencing (NGS) and array CGH (aCGH) were derived from existing literature [27, 28]. These costs were then checked for face validity with other members of the review team with experience of the provision. All costs are reported in 2020 Great British pound sterling (GBP), and where necessary cost were converted into 2020 GBP using the EPPI-Centre Cost Converter [29]. No cost for the G banding, karyotyping, mass spectrometry (MS) and NanoString techniques and comparative genomic hybridisation (CGH) was identified, as they are currently not routinely performed in the UK NHS and thus were not included. The model parameters are presented in Tables S1 and S2. The model was designed to generate the expected costs per true positive diagnosis, per true negative diagnosis and per correct diagnosis.

**Economic model: Sensitivity analysis**

A probabilistic sensitivity analysis (PSA) was carried out to address the uncertainty around the conclusions of the economic model. A PSA allows uncertainty caused by the imprecision surrounding the estimates used in the model examined simultaneously. Therefore, for each model parameter, a distribution was defined. A triangular distribution was used for cost values, and beta distributions were used for the prevalence, sensitivity and specificity values. Monte Carlo simulation was used to derive a distribution for cost and cost-effectiveness. In the Monte Carlo simulation, a set of parameter values is then drawn by randomly sampling from each distribution. For each iteration of model parameters, the model outputs were estimated. This sampling process was repeated 10,000 times to produce distributions for each of the specified model outputs.

**Deviation from protocol**

We had planned to perform a latent class analysis of all available data. We did not do this due to the complex structure of the data (with multiple studies involving different selections of test and different numbers of tests), which would involve development and validation of novel statistical methods. However, results from a limited latent class analysis of just FISH and PCR-based LOH are reported in the full Cochrane review.

**RESULTS**

**Search results and included studies**

Using the search methodology (Section 2), 5427 records were identified, and after removing duplicates, 3010 records were screened at title and abstract; 237 records were selected for full-text review, and 53 studies (in 78 publications) met the inclusion criteria. Assessments of risk of bias were mixed, due largely to lack of information about procedures in the study reports. The main issue of applicability was that many studies included only patients with specific subtypes of glioma.

**Presentation of study findings**

A network plot illustrates comparisons of test methods that were made among the included studies (Figure 3). A summary of the study findings and meta-analysis results is presented in Table 1. Tests that are relevant in clinical practice (PCR-based LOH, FISH, aCGH, SNP array, NGS, MLPA and real-time PCR) are shown with a brief explanation of the technique, and each test has been compared with one of the two index tests, FISH and PCR-based LOH, with separate listing of the quality of evidence, number of participants in the study, sensitivity, specificity, and an explanatory indication of the sensitivity and specificity, putting into a more intuitive context how many people with a positive test result achieved with index test (‘codeletion FISH detected’ or ‘codeletion PCR detected’) will have a correct positive, or a false positive result, and how many people with a detected non-
FIGURE 3  Network plot of the included studies. The colour scheme of the circles corresponds to the colour scheme of the test methods represented in Figures 4–7. The size of the circles represents the number of test results for a test category. The thickness of the lines is proportional to the number of studies making the comparison. Note that the FISH and PCR-based LOH circles include within-test category comparisons.

FIGURE 4  (A) Graphical representation of regions analysed in studies comparing four tests: Blesa 2009 [30], Hatanpaa 2003 [31] and Duval 2014 [32], and (B) studies comparing three tests: Mohapatra 2006 [33], Pesenti 2017 [34], Burger 2001 [35], Smith 1999 [36], Dahlback 2011 [37], Beldau-Rotureau 2006 [38], Horbinski 2012 [39] and Pesenti 2017 [34]. The top on both figures indicates a graphical representation of chromosome 1 (adapted from the GRCh38/hg38 Assembly). The figure legend indicates the different methods, with different colour codes for FISH, depending on the origin or manufacturer of the probes. In each section, the first author of the study is represented on top, and the techniques on the left of the table. All acronyms are explained in the main text.
FIGURE 5  (A) Graphical representation of regions analysed in studies comparing two tests: aCGH and FISH (Byeon 2014 [40]), aCGH and PCR (Blesa 2009 [30] and Byeon 2014 [40]), CGH and FISH (Smith 1999 [36]), CGH and G banding (Dahlback 2009 [41] and Schrock 1994 [42]), CGH and MLPA (Jeukem 2006 [43]), and CGH and PCR (Bigner 1999 [44] and Smith 1999 [36]), and (B) CISH and FISH (Lass 2013 [45]), FISH and FISH (Duval 2015 [46], Senetta 2013 [47], Srebotnik-Kirbis 2016 [48] and Uchida 2019 [49]), FISH and MLPA (Natté 2005 [50]), and FISH and NGS (D’Haene 2005 [51], Na 2019 [52], Park 2019 [53] and Sim 2018 [54]). The top of the figure indicates a graphical representation of chromosome 1 (adapted from the GRCh38/hg38 Assembly). For legend to symbols, see Figure 4

FIGURE 6  (A) Graphical representation of regions analysed in studies comparing two tests: FISH and PCR (Bouvier 2004 [55], Broholm 2008 [56], Clark 2013 [57], Gadji 2009 [58], Jha 2011 [59] and Scheie 2006 [60]), FISH and real-time PCR (Chaturbedi 2011 [61] and Nigro 2001 [62]), and FISH and SNP array (Ghasimi 2016 [63], Hinrichs 2016 [64] and Lhotska 2015 [65]), and (B) G banding and RFLP (Ransom 1992a [66] and Ransom 1992b [67]), methylation array (SNP readout) and MLPA (Wiestler 2014 [68]), NGS and PCR (Dubink 2016 [69]), and SNP array and PCR (Harada 2011 [70] and Tsilis 2010 [71]). The top of the figure indicates a graphical representation of chromosome 1 (adapted from the GRCh38/hg38 Assembly). For legend to symbols, see Figure 4
codeletion have a correct negative or a false negative result. The table indicates the outcome from the assessment using the GRADE approach [73, 74] with certainty of evidence ('high', 'moderate', 'low' or 'very low'), considering risk of bias, imprecision, inconsistency, indirectness and publication bias, all of which may lead to downgrading the quality of the evidence. All tests performed are also graphically represented in Figures 4–7.

Comparison of studies with FISH as reference standard

From the included studies that performed FISH (Figure 7B) and at least one other test that was not a FISH variant, we created 41 cross-classified $2 \times 2$ tables, with FISH as the reference standard (Table 1). FISH was compared with 10 different test categories: PCR-based LOH (15 comparisons), SNP array (6), NGS (6), CGH (4), aCGH (3), MLPA (2), real-time PCR (2), CISH (1), MS (1) and NanoString (1). The forty-one $2 \times 2$ tables came from 33 studies: 26 studies compared FISH with one other test, 6 studies compared FISH with two other test categories and 1 study compared FISH with three other test categories (Figures 4–7). The main results from the bivariate meta-analysis model indicate that sensitivity and specificity were generally high, though with wide credible intervals for most tests, and some results are based on very small numbers of patients, such as the result for mass spectrometry, which is based on a single study of 10 people. Our GRADE assessments for all tests were either 'low' or 'very low'.

Comparison of studies with PCR-based LOH as reference standard

From the included studies that performed PCR-based LOH (Figure 7B) and at least one other test that was not a PCR-based LOH
variability of being cost-effective at a WTP of £10,000. By comparison, when PCR-LOH was used as the reference standard, MLPA had a 100% probability of being considered the most costly of the five tests. MLPA also had the highest probability of being cost-effective in terms of true positives, true negative and correct diagnoses at a WTP up to £10,000. However, at £5000 and £10,000, no test had a probability of being cost-effective above 55%.

Results from economic model

The results for the base case of the economic model are summarised in Table S1 (FISH as reference standard) and Table S2 (PCR-based LOH as reference standard). A prevalence of 0.31 was used on the basis of the included studies in the meta-analysis. For several of the techniques in the meta-analysis, there is a smaller number of studies or participants, and therefore, the point estimates in Tables S1 and S2 must be interpreted with caution.

Sensitivity analysis

The results of the sensitivity analysis are displayed in Tables S1 and S2. The cost-effectiveness was compared with a number of different thresholds of societal willingness to pay (WTP) for the three outcomes: (i) cost per true positive, (ii) cost per true negative outcome or (iii) cost per case detected. These thresholds ranged from £0 (i.e., the decision is made on cost alone, and the test with the lowest cost would always be considered the most cost-effective) to £10,000 (i.e., the amount willing to be paid for an additional unit of effect such as an additional true positive detected). When considering FISH as the reference standard, MLPA is the most likely to be considered cost-effective. The other tests do have greater likelihood becoming cost-effective at higher financial thresholds, but MLPA remains the most likely to be cost-effective. The same is true for cost per true negative: For correct diagnosis, real-time PCR had the highest probability of being cost-effective at a WTP of £500 and £1000, and aCGH had the highest probability of being cost-effective at a WTP of £5000 and £10,000. However, none of the seven tests compared over a range of thresholds had a probability of test being cost-effective over 60%. By comparison, when PCR-LOH was used as the reference standard, MLPA had a 100% probability of being considered the least costly of the five tests. MLPA also had the highest probability of being cost-effective in terms of true positives, true negative and correct diagnoses at a WTP up to £10,000. However, at £5000 and £10,000, no test had a probability of being cost-effective above 55%.

DISCUSSION

To our knowledge, this is the first systematic review of the DTA of different techniques for assessing 1p/19q codeletion in glioma. We undertook a thorough search, applied systematic methods and assessed results for risk of bias using the QUADAS-2 tool.

The systematic review found that most techniques, except G banding, have a very good sensitivity when comparing with FISH or PCR-based LOH assay. G banding has a low sensitivity and specificity, but is no longer in routine laboratory use. Mass spectroscopy has a high sensitivity and specificity based on comparison with FISH and PCR-based LOH, but data are based on a single study and the technology is not used in clinical diagnostic use. NGS and SNP array had high specificity when compared against FISH and also PCR-based LOH, which is expected as these techniques determine entire chromosomal arms. This is of clinical importance, as in particular NGS is an expanding technology and increasingly used in diagnostic services. Whilst SNP arrays as such are rarely used nowadays, SNP data are determined from DNA methylation arrays, which are commonly used in brain tumour diagnostics [75–80]. The illustration in Figure 1 shows the location of probes on the 1p chromosome. Our test accuracy results confirm previous studies [17], showing that there is no difference in the HR for overall survival between studies using two different techniques, PCR-based LOH and FISH.

A technique of increasing importance is methylation array profiling. It is primarily used to establish epigenetic profiles of brain tumours, but the array data also generate a copy number profile with the added benefit of visualising chromosomal aberrations including 1p/19q codeletion [75, 76, 78–80]. This has been reported in two comparative studies [81, 82].

The limitation of our evaluation is the analysis of studies with FISH and PCR-based LOH as reference standards, and none of the investigated tests can be found to be superior to the reference standard assumed. Consequently, we were unable to include the results of studies that did not investigate either FISH or PCR-based LOH in the statistical synthesis. Most studies did not distinguish between absolute and relative deletions, and even if technically possible, it was rarely reported. Furthermore, loss of 1p and 19q in combination with 1q and/or 19p was considered by some studies to count as 1p/19q codeletion, but not in others. When we had to interpret the results of techniques, we did so by looking for the presence/absence of 1p and 19q without consideration of 1q and 19p.

The current definition of oligodendrogliomas requires the presence of an IDH mutation combined with a 1p/19q codeletion [13], and therefore, the inclusion criteria of previous studies and clinical trials, when based on histological diagnosis, would not be valid nowadays. Therefore, statements such as ‘1p/19q codeletion allow for prognostication and prediction of the best drug response’ have to be viewed also in historical context. However, this statement could still be considered as adequate in the context of IDH-mutant tumours as the 1p/19q codeletion delineates oligodendrogliomas from IDH-mutant astrocytomas.
This economic decision model was the first to consider the costs and benefits of diagnostic test methods of identifying 1p and 19q status. When evaluating the results generated by the economic model, it is important to consider its limitations. One such limitation is around certain model inputs, some of which were derived from a single hospital estimate (laboratory costs, though we did conduct some checks on the face validity of these estimates) or study (some sensitivity and specificity estimates). To address this, distributions were attached to parameter estimates as part of the PSA, but future research could provide a wider range of real-world parameters to explore the certainty of the model conclusions. Another limitation of this model is the limited time horizon. The model at present includes healthcare costs to derive the diagnosis of 1p and 19q status. However, assessing the long-term costs and consequences of the diagnosis could have significant resource implications. For example, the costs and health impacts of outcomes such as a correct diagnosis or impacts of a false negative are not included in this model. Future research could focus on the long-term implications of diagnosis of 1p/19q status and the impacts on treatment and health outcomes. This would allow testing strategies to be more fully evaluated and inform future decisions regarding diagnostic techniques.

Another parameter of practical importance, which could not be explored in the review is the time required to perform tests, which can indirectly impact cost-effectiveness. Depending on the laboratory setting, PCR-based tests for codeletion are considered less time-consuming than FISH [83], in particular when performed alongside other tests requiring DNA extraction (IDH1 and IDH2 sequencing, and MGMT promoter methylation), whereas another study has reported no difference of turnaround time between FISH and real-time reverse transcription PCR [84]. FISH may still be time effective in small-volume settings and where dedicated technical staff are readily available. NGS approaches or methylation arrays require batching of samples and are currently less time effective, perhaps with the exception in high-volume services. These techniques however offer a such significant additional information content, often allowing a conclusive diagnosis in a single assay, that this can compensate for the longer turnaround. Novel technologies, such as nanopore sequencing, are emerging, and these could significantly reduce testing times [85, 86].

In conclusion, the diagnosis of oligodendroglioma, IDH mutant and 1p/19q codeleted requires the demonstration of 1p/19q codeletion [10, 11, 87], but there is little consensus regarding the best approach. Our review suggests that all techniques except G banding have high sensitivity when compared against FISH or PCR-based LOH as a reference standard, with NGS and SNP array having high specificity against FISH and PCR-based LOH. This suggests that NGS and SNP array techniques can be used with confidence for detection of 1p/19q codeletion in the place of FISH or PCR-based LOH, which may be advantageous as these techniques are capable of simultaneously detecting other abnormalities. The use of methylation arrays for brain tumour diagnostics is a recent development. The copy number information (equivalent to SNP data) of the arrays generates a diagnostic readout in addition to the high diagnostic value of a methylation class as described in the Cochrane review. The results of an accompanying economic model highlight potentially promising strategies for future research, but these results are compounded by a lack of data to parameterise the model and a limited time horizon. Future research can focus on deriving more longitudinal data to inform future economic evaluation studies assessing the long-term health costs and consequences of such strategies.

ACKNOWLEDGEMENTS

We thank Robin Grant (Co-ordinating Editor) and Gail Quinn (Managing Editor) from the Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Group (GNOC) for editorial guidance. We also thank Joanne Platt (Information Specialist, GNOC) for aiding with the early development of the search strategy. We are grateful to Luke McGuinness for creating customised QUADAS-2 plots and Hung-Yuan Cheng for creating the network plot. We also thank Hung-Yuan Cheng and Tony Ades for reading and commenting on a draft of the protocol. We thank the Cochrane DTA team and all of our external peer reviewers, including Helen Bulbeck, Mike Jenkinson and Dwayne Boyers. This project was supported by the National Institute for Health Research (NIHR), via Cochrane Programme Grant funding to the GNOC. A. M. and J. P. T. H. are supported in part by Cancer Research UK (Grant Numbers C18281/A19169 and C18281/A29019). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS) or the Department of Health and Social Care, or Cancer Research UK. S. B. is also supported by the Department of Health’s NIHR Bristol Biomedical Research Centre’s funding scheme to UCLH. H. E. J. was supported by an MRC-NIHR New Investigator Research Grant (MR/T044594/1).

AUTHOR CONTRIBUTIONS

A. M., L. S., S. D., E. S. L. and C. L. F. performed the title/abstract screening. A. M., L. S., E. S. L. and J. P. T. H. performed the full-text screening. A. M., L. S., C. K., E. S. L., A. P., J. P. T. H. and K. M. K. performed the data extraction. S. D. undertook the searches. A. M., L. S., C. K., J. P. T. H. and K. M. K. undertook the QUADAS-2 assessments. H. E. J. performed the statistical analyses. A. K. and T. R. performed the economic analyses. J. P. T. H. performed the GRADE assessments. A. M. managed the project. J. P. T. H., L. V. and H. E. J. provided the methodological expertise. K. M., S. B., C. L. F. and C. W. provided the content expertise. A. M., H. E. J., A. K., T. R., S. B., L. V., J. P. T. H. and K. M. K. drafted the manuscript. All authors commented on the manuscript.

CONFLICT OF INTERESTS

The authors declare no conflicts of interest.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/nan.12790.
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analysed in this study.

ORCID
Sebastian Brandner https://orcid.org/0000-0002-9821-0342

REFERENCES
1. Pinkham MB, Telford N, Whitfield GA, Colaco RJ, O'Neill F, McBain CA. FISHing tips: what every clinician should know about 1p/19q analysis in gliomas using fluorescence in situ hybridisation. Clin Oncol (R Coll Radiol) 2015;27(8):445-453.
2. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006;65(10):988-994.
3. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20):9852-9861.
4. Chamberlain MC, Born D. Prognostic significance of relative 1p/19q codeletion in oligodendrogliomas. J Neurol Oncol. 2015;125(2):249-251.
5. Ren X, Jiang H, Cui X, et al. Co-polysonomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglioma tumors: FISH analysis of 148 consecutive cases. Neuro Oncol. 2013;15(9):1244-1250.
6. Snuderl M, Eichler AF, Ligon KL, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009;15(20):6430-6437.
7. Jiang H, Ren X, Cui X, et al. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol. 2013;15(6):775-782.
8. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820.
9. Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. J Neuropathol Exp Neurol. 2020;139(3):777-782.
10. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Driscoll P, Bond M, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
12. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
13. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
14. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
15. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
16. Hu N, Richards R, Jensen R. Role of chromosomal 1p/19q co-deletion on the prognosis of oligodendrogliomas: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2015;92(3):638-645.
17. Zhao J, Ma W, Zhao H. Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol. 2014;16(1):103-112.
18. Jiang H, Ren X, Zhang Z, Zeng W, Wang J, Lin S. Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendrogliomas. J Neurol Oncol. 2014;120(1):131-138.
19. Messali A, Villacorta R, Hay JW. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014;32(12):1201-1212.
20. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
21. Hoefler D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
22. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
23. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
24. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
25. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
26. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
27. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
28. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
29. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
30. Thomas J, Graziosi S, Brunton J, Ghouze Z, O’Driscoll P, Bond M. EPPI-Reviewer: Advanced Software for Systematic Reviews, Maps and Evidence Synthesis. London: EPPI-Centre Software UCL Social Research Institute; 2020.
31. Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KM, Berg KD. Molecular genetics of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014;32(12):1201-1212.
32. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
33. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
34. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
35. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
36. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
37. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
38. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
39. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
40. McAleenan A, Jones HE, Kernohan A, et al. Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. Cochrane Database Syst Rev. 2019;8:CD013837.
38. Dahlback HS, Gorunova L, Brandal P, et al. Genomic aberrations in diffuse low-grade gliomas. Genes Chromosomes Cancer. 2011;50(6):409-420.

39. Belaud-Rotureau MA, Meunier N, Eimer S, Vital S, Loiseau H. Automated assessment of 1p36-19q13 status in gliomas by interphase FISH assay on touch imprints of frozen tumours. Acta Neuropathol. 2006;111(3):255-263.

40. Byeon SJ, Cho HJ, Baek HW, et al. Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Hum Pathol. 2014;45(3):611-620.

41. Dahlback HS, Brandal P, Meling TR, Michaud K, et al. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn. 2006;8(4):433-443.

42. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol. 1999;144(6):1203-1218.

43. Jeuken J, Cornelissen S, Boots-Sprenger P, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glioblastoma. J Mol Diagn. 2006;8(4):433-443.

44. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol. 1999;155(2):375-386.

45. Lass U, Hartmann C, Capper D, et al. Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol. 2013;23(3):311-318.

46. Duval C, de Tayrac M, Michaud K, et al. Automated analysis of 1p/19q status by FISH in oligodendrogliomas: rationale and proposal of an algorithm. PLoS ONE. 2015;10(7):e0132125

47. Senetta R, Verdun di Cantogno L, Chiusa L, et al. The importance of 10q amplification for the detection of 1p and 19q chromosomal loss in oligodendrogliomas. Acta Neuropathol. 2006;111(3):255-263.

48. Uchida H, Yonezawa H, Hirano H, Yoshimoto K. Abstracts of the XIX International Congress of Neuropathology, Tokyo, Japan, September 23–27, 2018. Brain Pathol. 2019;29(Suppl 1):1-398.

49. Natté R, van Eijk R, Eilers P, et al. Detection of 1p/19q deletion in oligodendrogliomas. J Neuropathol Exp Neurol. 2013;72(5):432-441.

50. Srebotnik-Kirbis I, Limback-Stokin C. Application of brush cytology in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol. 2001;14(9):842-853.

51. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18(28):4144-4152.

52. Senetta R, Verdun di Cantogno L, Chiusa L, et al. A real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158(4):1253-1262.

53. Dahlin AM, Ghasimi S, Wibom C, et al. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. J Neurooncol. 2016;127(3):483-492.

54. DINOPTO A, Cappelletti M, et al. The diagnostic potential of next-generation sequencing in glioma. Sci Rep. 2016;6(1):23262.

55. Harada S, Henderson LB, Eshleman JR, et al. Genomic changes in gliomas detected using single nucleotide polymorphism array in situ hybridization. Acta Neuropathol. 2014;127(5):493-501.

56. Natté R, van Eijk R, Eilers P, et al. Detection of 1p/19q deletion in oligodendroglioma. J Neurooncol. 2006;70(1):73-82.

57. Byeon SJ, Cho HJ, Baek HW, et al. Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Hum Pathol. 2014;45(3):611-620.

58. Dahlback HS, Brandal P, Meling TR, Michaud K, et al. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in gliomas. J Mol Diagn. 2006;8(4):433-443.

59. Schröck E, Thiel G, Lozanova T, et al. Comparative genomic hybridization of human malignant glioma reveals multiple amplification sites and nonrandom chromosomal gains and losses. Am J Pathol. 1994;144(6):1203-1218.

60. Jeuken J, Cornelissen S, Boots-Sprenger P, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glioblastoma. J Mol Diagn. 2006;8(4):433-443.

61. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol. 1999;155(2):375-386.

62. Lass U, Hartmann C, Capper D, et al. Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol. 2013;23(3):311-318.

63. Duval C, de Tayrac M, Michaud K, et al. Automated analysis of 1p/19q status by FISH in oligodendrogliomas: rationale and proposal of an algorithm. PLoS ONE. 2015;10(7):e0132125

64. Senetta R, Verdun di Cantogno L, Chiusa L, et al. A “weighted” fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q co-deletion in pure and mixed oligodendroglioma. J Neuropathol Exp Neurol. 2013;72(5):432-441.

65. Srebotnik-Kirbis I, Limback-Stokin C. Application of brush cytology for FISH-based detection of 1p/19q co-deletion in oligodendrogliomas. J Neurooncol. 2016;129(3):415-422.

66. Uchida H, Yonezawa H, Hirano H, Yoshimoto K. Abstracts of the XIX International Congress of Neuropathology, Tokyo, Japan, September 23–27, 2018. Brain Pathol. 2019;29(Suppl 1):1-398.

67. Natté R, van Eijk R, Eilers P, et al. Multiplex ligation-dependent probe amplification for the detection of 1p and 19q chromosomal loss in oligodendrogliomas. Brain Pathol. 2005;15(3):192-197.

68. D’Haene N, Melendez B, Blanchard O, et al. Design and validation of a gene-targeted, next-generation sequencing panel for routine diagnosis in gliomas. Cancer. 2019;119(6):773

69. Na K, Kim HS, Shim HS, Chang JH, Kang SG, Kim SH. Targeted next-generation sequencing panel (TruSight Tumor 190) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol. 2019;142(3):445-454.
formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis. J Mol Diagn. 2011;13(5):541-548.

71. Tsiantis AC, Hafez MJ, Jedlicka AE, Maht A, Murphy KM, Eshleman JR. Use of SNP arrays to assess loss of heterozygosity in gliomas [abstract nr 1781]. Cancer Res. 2010;70. https://cancerres.aacrjournals.org/content/70/8_Supplement/1781

72. Cowell JK, Barnett GH, Nowak NJ. Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGH). J Neuropathol Exp Neurol. 2004;63(2):151-158.

73. Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106-1110.

74. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.

75. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-474.

76. Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol Commun. 2018;7(1):24.

77. Jaunmuktane Z, Capper D, Jones DTW, et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol Commun. 2019;7(1):185.

78. Karimi S, Zuccato JA, Mamatjan Y, et al. The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clin Epigenetics. 2019;11(1):185.

79. Priesterbach-Ackley LP, Boldt HB, Petersen JK, et al. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. Neuropathol Appl Neurobiol. 2020;46(5):478-492.

80. Pickles JC, Stone TJ, Jacques TS. Methylation-based algorithms for diagnosis: experience from neuro-oncology. J Pathol. 2020;250(5):510-517.

81. Wiestler B, Capper D, Hovestadt V, et al. Determining the glioma Cpg island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. J Clin Oncol. 2014;32(15_suppl):2017

82. Kessler T, Berberich A, Casalini B, et al. Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol Adv. 2020;2(1):vdx060

83. Hout DR, Schweitzer BL, Lawrence K, et al. Performance of a RT-PCR assay in comparison to FISH and immunohistochemistry for the detection of ALK in non-small cell lung cancer. Cancer. 2017;9(12).

84. Lassman AB, Roberts-Rapp L, Sokolova I, et al. Comparison of biomarker assays for EGFR: implications for precision medicine in patients with glioblastoma. Clin Cancer Res. 2019;25(11):3259-3265.

85. Euskirchen P, Bielle F, Labreche K, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathol. 2017;134(5):691-703.

86. Patel A, Dogan H, Payne A, Sievers P, Schoebe N, Schrimp D, Stichel D, Holmes N, Euskirchen P, Hench J, Frank S, Rosenstiel-Goidts V, Ratliff M, Etminan N, Unterberg A, Dieterich C, Herold-Mende C, Pfister SM, Wick W, Schlesner M, Loose M, von Deimling A, Sill M, Jones DTW, Sahm F. Rapid-CNS: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study. medRxiv 2021: 2021.08.09.21261784

87. National Institute for Health and Care Excellence. Brain tumours (primary) and brain metastases in adults. NICE guideline [NG99]. 2018. https://www.nice.org.uk/guidance/ng99

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Brandner S, McAleenan A, Jones HE, et al. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review. Neuropathol Appl Neurobiol. 2022;48(4):e12790. doi:10.1111/nan.12790